INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 412m ago
HOUSE PTR12m ago
SEC 13F12m ago
ROBINHOOD CHAIN12m ago
SEC FORM 4/Grant or awardVerified data

Morgen Eric reported BIOA

Director, Chief Operating Officer · BioAge Labs, Inc. · BioAge Labs, Inc. — Stock Option (Right to Buy)

Side
A
Value
—
Shares
110.0K
Price
—
Executed
Feb 17, 2026
Disclosed
Feb 19, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Feb 17 executedFeb 19, 2026 disclosed

BIOA · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · BIOA

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    5
    FK
    Fortney KristenDirector, Chief Executive Officer
    BIOABioAge Labs, Inc.
    Grant or award
    		A—
    330.0K sh
    		Feb 17, 2026Feb 19, 2026
    traded Feb 17, 2026
    		+2dSEC FORM 4

    Evidence

    9
    ME
    Morgen EricDirector, Chief Operating Officer
    BIOABioAge Labs, Inc.
    Grant or award
    		A—
    12.5K sh
    		Feb 17, 2026Feb 19, 2026
    traded Feb 17, 2026
    		+2dSEC FORM 4

    Evidence

    18
    FK
    Fortney KristenDirector, Chief Executive Officer
    BIOABioAge Labs, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$4.22M
    233.1K sh
    		Jan 13, 2026Jan 15, 2026
    traded Jan 13, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002036289-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Feb 17, 2026
    Published
    Feb 19, 2026
    Ingested by INSIDER
    Nov 5, 04:16 UTC
    Last re-read
    Nov 5, 04:16 UTC

    Extracted facts

    Filer
    Morgen Eric
    Role
    Director, Chief Operating Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    BioAge Labs, Inc. — Stock Option (Right to Buy)
    Ticker
    BIOA
    Shares
    110.0K
    Price per share
    $0
    Execution date (reported)
    Feb 17, 2026
    Owned after transaction
    110.0K shares
    Days from execution to publication
    2

    What this establishes

    Morgen Eric filed this Form 4 reporting a grant or award of BIOA on Feb 17, 2026. It became public on Feb 19, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, Chief Operating Officer
    Morgen Ericcik:0002036289
    Issuer
    BioAge Labs, Inc.cik:0001709941

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.